About Skyhawk Therapeutics
Skyhawk Therapeutics is a company based in Waltham (United States) founded in 2017. Skyhawk Therapeutics has raised $181 million across 3 funding rounds from investors including Fidelity Investments, ARE and Disney. Skyhawk Therapeutics operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others.
- Headquarter Waltham, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$181 M (USD)
in 3 rounds
-
Latest Funding Round
$133 M (USD), Series B
Sep 14, 2021
-
Investors
Fidelity Investments
& 7 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Skyhawk Therapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Skyhawk Therapeutics
Skyhawk Therapeutics has successfully raised a total of $181M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $133 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Skyhawk Therapeutics
Skyhawk Therapeutics has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, ARE and Disney.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Agent Capital is focused on healthcare venture capital investments.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on early-stage big data, health tech, AI, food tech, and multiple sectors
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Skyhawk Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Skyhawk Therapeutics
Investment portfolio details for Skyhawk Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Skyhawk Therapeutics
Detailed financials for Skyhawk Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Skyhawk Therapeutics Comparisons
Peer comparison for Skyhawk Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Skyhawk Therapeutics
Skyhawk Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of drugs for solid tumours and blood cancers
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| Locked | Locked | Locked |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| Locked | Locked | Locked |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| Locked | Locked | Locked |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
Detailed competitors of Skyhawk Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Skyhawk Therapeutics
Complete news archive for Skyhawk Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Skyhawk Therapeutics
Skyhawk Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Skyhawk Therapeutics is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Skyhawk Therapeutics is a funded company, having raised a total of $181M across 3 funding rounds to date.
Founded in 2017 and based in Waltham, United States, small molecules that modify RNA are discovered by Skyhawk Therapeutics for applications in neurodegenerative, oncology, neuromuscular, rare, and other diseases. Proprietary structural, kinetic, and computational models are utilized to identify these candidates. Operations focus on advancing therapies across various therapeutic areas within the biotechnology sector.
Skyhawk Therapeutics's top competitors include Nuvalent, Enliven Therapeutics and Abbisko Therapeutics.
Skyhawk Therapeutics has 8 investors. Key investors include Fidelity Investments, ARE, Disney, Good Growth Capital, and Agent Capital.